Publications by authors named "Salma Lamrabet"
Article Synopsis
- Glioblastoma (GBM) is a very common and aggressive brain tumor, with standard treatments like surgery and chemotherapy not significantly improving patient outcomes.
- *Current research is focusing on immunotherapy methods such as vaccines and T-cell therapies, which are showing encouraging results in trials.
- *The review discusses the challenges of immunotherapy, identifies key biomarkers as potential therapeutic targets, and suggests strategies to enhance the effectiveness of treatments for GBM.
Introduction: Glioblastoma and astrocytoma, grade 4, are the most common and aggressive brain tumors. Several biomarkers, such as the isocitrate dehydrogenase mutation (IDH-1), alpha-thalassemia/mental retardation, and the X-linked mutation (ATRX), enable more accurate glioma classification and facilitate patient management. This study aimed to determine the prognostic value of clinical and molecular factors (IDH, TP53, and ATRX mutations).
View Article and Find Full Text PDFArticle Synopsis
- Triple-negative breast cancer (TNBC) is a subtype of breast cancer that doesn't express hormone receptors or HER2, and is known for its aggressive nature and high rates of metastasis and relapse.
- The review discusses the various molecular subtypes and biomarkers associated with TNBC, focusing on elements that regulate cell behavior, DNA damage, and immune responses.
- Additionally, it highlights advanced research methods like genomics and transcriptomics for understanding TNBC further, and mentions new treatment options including immunotherapy and targeted therapies.
Glioblastoma is the most aggressive malignant tumor of the central nervous system with a low survival rate. The difficulty of obtaining this tumor material represents a major limitation, making the real-time monitoring of tumor progression difficult, especially in the events of recurrence or resistance to treatment. The identification of characteristic biomarkers is indispensable for an accurate diagnosis, the rigorous follow-up of patients, and the development of new personalized treatments.
View Article and Find Full Text PDF